Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019
Preprint
Abstract
Background: Since late December, 2019, an outbreak of pneumonia cases caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and continued to spread throughout China and across the globe. To date, few data on immunologic features of Coronavirus Disease 2019 (COVID-19) have been reported. Methods: In this single-centre retrospective study, a total of 21 patients with pneumonia who were laboratory-confirmed to be infected with SARS-CoV-2 in Wuhan Tongji hospital were included from Dec 19, 2019 to Jan 27, 2020. The immunologic characteristics as well as their clinical, laboratory, radiological features were compared between 11 severe cases and 10 moderate cases. Results: Of the 21 patients with COVID-19, only 4 (19%) had a history of exposure to the Huanan seafood market. 7 (33.3%) patients had underlying conditions. The average age of severe and moderate cases was 63.9 and 51.4 years, 10 (90.9%) severe cases and 7 (70.0%) moderate cases were male. Common clinical manifestations including fever (100%, 100%), cough (70%, 90%), fatigue (100%, 70%) and myalgia (50%, 30%) in severe cases and moderate cases. PaO2/FiO2 ratio was significantly lower in severe cases (122.9) than moderate cases (366.2). Lymphocyte counts were significantly lower in severe cases (0.7 × 10□/L) than moderate cases (1.1 × 10□/L). Alanine aminotransferase, lactate dehydrogenase levels, high-sensitivity C-reactive protein and ferritin were significantly higher in severe cases (41.4 U/L, 567.2 U/L, 135.2 mg/L and 1734.4 ug/L) than moderate cases (17.6 U/L, 234.4 U/L, 51.4 mg/L and 880.2 ug /L). IL-2R, TNF-α and IL-10 concentrations on admission were significantly higher in severe cases (1202.4 pg/mL, 10.9 pg/mL and 10.9 pg/mL) than moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 pg/mL). Absolute number of total T lymphocytes, CD4 + T cells and CD8 + T cells decreased in nearly all the patients, and were significantly lower in severe cases (332.5, 185.6 and 124.3 × 10 6 /L) than moderate cases (676.5, 359.2 and 272.0 × 10 6 /L). The expressions of IFN-γ by CD4 + T cells tended to be lower in severe cases (14.6%) than moderate cases (23.6%). Conclusion: The SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4 + T cells, resulting in significant decrease in number as well as IFN-γ production, which may be associated with disease severity. Together with clinical characteristics, early immunologic indicators including diminished T lymphocytes and elevated cytokines may serve as potential markers for prognosis in COVID-19.Keywords
All Related Versions
- Published version: Journal of Clinical Investigation, 130 (5), 2620.
This publication has 17 references indexed in Scilit:
- Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome CoronavirusThe Journal of Infectious Diseases, 2015
- Identification and Clinical Relevance of Naturally Occurring Human CD8+HLA-DR+ Regulatory T CellsThe Journal of Immunology, 2014
- Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus InfectionAnnals of Internal Medicine, 2014
- Rapid generation of a mouse model for Middle East respiratory syndromeProceedings of the National Academy of Sciences, 2014
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012
- Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+T Cells Are Important in Control of SARS-CoV InfectionJournal of Virology, 2010
- Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsetsInternational Journal of Infectious Diseases, 2005
- p47 GTPases: regulators of immunity to intracellular pathogensNature Reviews Immunology, 2004
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003
- Corticosteroid‐Mediated Immunoregulation in ManImmunological Reviews, 1982